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ABSTRACT 
 
   A number of gene therapy clinical trials are being carried out the world over. Gene therapy is being 
applied in (I) cancer diseases, involving the largest number of patients, (II) monogenic diseases, 
(III) infectious diseases, (IV) vascular diseases, (V) autoimmune diseases and others. In the last 
decade, several strategies of cancer gene therapy have emerged due to a rapid development of gene 
delivery systems, both viral (recombinant retroviruses, adenoviruses, AAVs, herpes viruses) and non-
viral (liposomes, gene guns, electroporation). To date four main strategies of cancer gene therapy 
have been evaluated in clinical trials: (I) immunogene therapy, (II) suicide gene therapy, (III) antiangio-
genic gene therapy, (IV) and administration of tumour suppressor genes. 
   These strategies mostly involve: malignant melanoma, prostate cancer, renal cell cancer, colon can-
cer, breast and ovarian cancers, lung cancers, neoplastic diseases of the blood and brain tumours. 
   At the Department of Cancer Immunology at the GreatPoland Cancer Center Gene Modified Tumour 
Vaccine has been tested in malignant melanoma patients for more than six years. Due to encouraging 
results from phase I and II of clinical trials a phase III was designed and will be started in 2003. 
   Key words: cancer gene therapy, viral vectors, immnotherapy, antiangiogeic therapy, suicide therapy. 
 
   Gene therapy is one of the fastest deve-
loping fields of medicine. Throughout 
the world about 500 clinical trials are being 
carried out in order to evaluate the effi-
ciency of this treatment in different dise-
ases. There are several fields of applica-
tion of gene therapy: (I) cancer therapy, 
which involves the largest number of pa-
tients participating in clinical trials, (II) the-
rapy of monogenic diseases, (III) infectious 
diseases, (IV) vascular diseases and others. 
Although the first clinical trial of gene 
therapy was started in 1992, currently, 
the majority of clinical protocols are still 
in phase I, phase I/II, and, as yet, there 
are only a few phase III studies. 
There are four major strategies of cancer 
gene therapy: (I) immunogene therapy, 
(II) suicide gene therapy, (III) correction 
of tumour suppressor genes and (IV) anti-
angiogenic gene therapy. 
 
GENE DELIVERY SYSTEMS 
 
   One of the major challenges in gene 
therapy is the delivery of therapeutic 
gene(s) to target cells. Several gene trans-
ferring systems are used for this purpose 
and they can be divided into two groups: 
non-viral methods (comprising injection 
of naked DNA [1,2], “gene gun” [3,4] and 
liposomes [5,6] etc.) and viral methods, 
which include gene delivery systems con-
structed on the basis of different viruses. 
The viral gene delivery systems, currently 
used in clinical protocols involve retroviral 
vectors, recombinant adenoviruses and 
pox-viruses, adenoassociated vectors and 
herpes simplex vectors. Recombinant 
retroviral vectors were used in the first 
protocol of gene therapy, carried out 
in 1992 by Rosenberg at al [7]. The Molo-
ney Murine Leukemia Virus (MoMLV)-
based retroviral vectors are the most po-
pular viral gene delivery vehicles used 
in clinical protocols so far (35.8%) [8,9]. 
They transduce dividing cells and integrate 
viral genome with the genome of host 
cells. Recombinant retroviruses are mostly 
used for the production of cancer vacci-
nes. They introduce therapeutic genes into 
cancer cells ex vivo, thus creating a stable 
genetically modified cancer cell lines. 
Although most of gene therapy protocols 
use retroviral vectors, they are not the best 
tool to modify cancer cells in vivo. 
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Recombinant retroviruses cannot be grown 
to high titres, can transduce only dividing 
cells and are ineffective when admini-
stered in vivo because of rapid destruction 
by complement complex in serum [10] 
   Adenoviral vectors are used in more 
than 25% of clinical protocols [9]. They are 
becoming more and more popular be-
cause of some features they demonstrate: 
there is an established, relatively easy 
production system, adenoviruses can be 
produced in high titres, show high trans-
duction efficiency and can be effectively 
administered in vivo. There are three ge-
nerations of adenoviruses. The first gene-
ration is highly immunogenic [11]. The 1st 
generation adenoviral vectors lack only 
one adenoviral sequence – E1, thus 
the therapeutic gene is delivered to target 
cells along with the rest of viral genes. 
The remaining adenoviral sequences indu-
ce a strong humoral and cellular immune 
response directed against AdV-modified 
cells. In the second generation of adenovi-
ral vectors some further adenoviral genes 
have been removed, but transduced cells 
still express a few products encoded by 
viral sequences [12]. The third generation 
of adenoviral vectors, so called “helper de-
pendent – gutless vectors”, has been con-
structed in Frank Graham’s laboratory [13]. 
They have removed all viral genes, thus 
creating an extremely low immunogenic 
vector, which can deliver very large 
(up to 30 kb) therapeutic genes. Although 
the production of gutless adenoviral vec-
tors is more complex than that of the first 
generation, the helper dependent system 
represents a very promising tool for gene 
therapy applications.  
   The viral vectors currently used in gene 
therapy protocols are still not an ideal tool 
for novel approaches in cancer gene the-
rapy such as genetic modification of stem 
cells. Popular recombinant viral vectors 
cannot deliver therapeutic genes to very 
early CD34+ progenitor cells and integrate 
their genome with a genome of non-divi-
ding host cells. Lentiviral vectors represent 
universal solution to these problems [14]. 
They can be produced in a high titre, can 
transduce and integrate with the genome 
of non-dividing cells and efficiently deliver 
therapeutic genes to CD34+ cells. The len-
tiviral vectors are derived from HIV which 
belongs to the complex retroviruses. 
Unlike simple retroviruses (MoMLV), which 
contain only three structural genes, lenti-
viruses comprise nine (three structural - 
gag, pol, env and six regulatory - Vif, Vpr, 
Vpu, Tat, Rev and Nef) genes. Production 
of the most sophisticated (3rd generation) 
HIV-based viral vectors requires a quadru-
ple transfection of 293 cells (three packa-
ging plasmids and one transfer vector) 
[15]. Although there are still some safety 
concerns associated with the fact that the 
HIV is a deadly pathogen in humans, the 
last generation of lentiviral vectors will 
undoubtedly be soon applied in clinical 
trials of gene therapy. 
 
CANCER IMMUNOGENE THERAPY 
 
   The first trial of cancer immunotherapy 
can be dated back to the 19th century, 
when Wiliam Coley used preparations de-
rived from streptococcal cultures to treat 
tumours. In some of his patients the can-
cer burden diminished or even disa-
ppeared. Molecular biology and genetic 
engineering have created a new era 
in cancer immunotherapy. In the last two 
decades, multiple genes encoding immu-
nostimulatory factors, MHC and costimula-
tory molecules have been synthesized, 
and now they are used in various gene 
therapy protocols. Tumour cells may be 
eliminated by the immune system by both 
cellular and humoral mechanisms [16,17, 
18]. Cellular cytotoxicity is believed to play 
a major role in anticancer immunity. 
Specific cytotoxicity is mediated by a sub-
population of T cells possessing a T-cell 
receptor (TCR) consisting of alpha-beta 
chains. The alpha-beta cells comprise two 
subgroups – CD4+ and CD8+ cells, which 
recognize tumour antigens on tumour cells 
in a context of MHCII and MHCI molecules, 
respectively. Non-specific cytotoxicity is 
mediated by NK cells which recognize 
tumour cells that do not express MHC 
molecules. This kind of immune response 
is not antigen specific, but it does not 
require prior contact of immune effectory 
cells with target cells. Humoral anti-tumour 
immunity is mediated by antibodies 
produced by activated B-cells. Antibodies 
can eliminate tumour cells in various ways 
– by activating complement, by opso-
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nization and antibody - dependent cellular 
cytotoxicity (ADCC) which is mediated 
by effectory cells, carrying Fc receptors. 
A key role in the induction of antigen 
specific immune response is played by 
professional antigen presenting cells 
(APCs) – dendritic cells (DC). DC behave 
as sentinels in the immune system. 
Immature DC are located in peripheral 
tissues and are characterized by a high 
phagocytic capacity, low expression of MHC 
and costimulatory molecules, and a low 
level of cytokine secretion. They capture 
and process various antigens, e.g. tumour 
antigens from apoptotic bodies or released 
from tumour cells destroyed in an antigen 
non-specific manner. Upon delivery 
of a ‘danger signal’ DC begin to mature. 
On the surface they upregulate MHC I and 
II molecules, costimulatory molecules 
(CD40, CD54, CD 80, CD86) and secrete 
cytokines. Maturing DC migrate towards 
draining lymph nodes, where they present 
tumour antigens in the context of MHC I 
or II molecules to CD8+ or CD4+ cells, 
respectively. Costimulatory molecules are 
necessary to provide a so called ‘second 
signal’, crucial for priming and activation 
of naïve T lymphocytes. IL-12 secreted by 
activated DCs acts on CD4+ cells and 
turns them into interferon-gamma (IFN-γ) 
producing Th1 cells. Such a polarized po-
pulation of Th cells has been demonstra-
ted to mediate a strong and long lasting 
antitumoural immune response. DCs are 
very effective in stimulating T cells, one 
DC can turn on 100 – 3,000 T cells [19].  
   Gene immunotherapy of cancer uses 
different immunological elements in order 
to elucidate an effective antitumoural im-
mune response. For example, genes en-
coding various cytokines ex vivo or in vivo 
(intratumourally) are introduced into can-
cer cells. Cancer cells secrete proteins en-
coded by genes introduced into the tumour 
microenvironment. Such immunostimula-
tory factors modulate the tumour micro-
environment and provide a danger signal 
attracting and activating professional 
APCs. Some cytokines (IL-2, IL-6, IL-12, 
IFN-γ) have been thought to directly 
activate killer cells (CD8+, NK). However, 
according to the current research, it seems 
that they mainly act as danger signals for 
DCs [20]. Tumour cells expressing cyto-
kines such as IFN-γ or IL-12, not only 
strongly activate dendritic cells, but also 
induce a strong polarization of immune 
response towards the functional Th1 cells 
[21].  
   Since 1996 at the Department of Cancer 
Immunology USOMS, Great Poland Can-
cer Centre in Poznań, Poland, a gene-
tically modified tumour vaccine (GMTV) 
has been tested in malignant melanoma 
patients. GMTV consisted of allogenic 
melanoma cells modified with genes en-
coding IL-6 and its agonistic soluble rece-
ptor (sIL-6R). For the last 5 years more 
than 220 patients have been enrolled 
in this study. More than 35% of clinical 
responses were observed. The encoura-
ging results became a basis for the design 
of a phase III randomized clinical trial 
which will be initiated in the 2003 [22].  
   Another approach to cancer gene immu-
notherapy is turning of tumour cells into 
antigen presenting cells. Tumour antigens 
are presented in the context of MHC-I 
molecules by most tumour cells. However, 
tumour cells, lacking costimulatory mole-
cules which provide a second signal nece-
ssary for proper activation of lymphocytes, 
induce an antigen-specific tolerance 
of these effectory cells. Introduction of ge-
nes encoding costimulatory molecules 
such as B7.1 or B7.2 was thought to revert 
the tumour induced tolerance and to elu-
cidate a strong antitumour immune res-
ponse mediated by CD8+ cells [23].  
   DCs as a key element in the induction 
of antitumoural immune response are pro-
mising targets for gene therapy. Introduc-
tion of genes encoding tumour antigens 
into DCs elucidates a strong antigen-
specific immune response mediated by 
CD4+ and CD8+ cells [24]. However, 
this approach has several disadvantages, 
e.g. modification of DC in vivo is extremely 
difficult, and isolation and propagation 
of these cells in vitro is a very time-
consuming process. Moreover, genetically 
modified and activated ex vivo DCs, after 
subcutaneous administration hardly mi-
grate into draining lymph nodes, thus sho-
wing much lower than expected efficacy 
in the induction of anti-tumour response. 
This method requires that a large number 
of gene modified DCs be injected into 
patients.  
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SUICIDE THERAPY OF CANCER 
 
   This concept is based on a direct deli-
very of a gene encoding enzyme, which 
can convert a non-toxic prodrug into its 
toxic metabolite [25]. Gancyclovir – a nu-
cleoside analogue is used in the treatment 
of patients infected by herpes viruses 
(HSV, VZV). Cells infected by a herpes 
virus produce thimidine kinase (TK) en-
coded by a viral genome, and, upon gan-
ciclovir administration, become unable 
to divide and subsequently die [5,26]. 
In order to treat cancer patients, a cDNA 
encoding TK may be directly delivered 
to tumour cells by adenoviruses, lentivi-
ruses, liposomes or by physical methods. 
A few days later, the patient receives 
intravenous administration of ganciclovir. 
Ganciclovir is transported with blood to all 
organs and tissues including tumours. This 
prodrug upon entry into a tumour cell, 
transduced with a vector encoding TK, be-
comes phosphorylated into its toxic meta-
bolite (ganciclovir triphosphate), which, 
by inhibition of DNA synthesis induces 
cell’s death. In a tumour mass, cancer 
cells are connected with each other via 
gaps junctions. In a process called ‘by-
stander effect’ phosphorylated form of gan-
cyclovir may spread from one genetically 
modified cell to anothers, where it exerts 
the same therapeutic effect [27]. Thanks 
to the ‘bystander effect’ not all cancer cells 
in a tumour mass have to be modified with 
the TK gene in order to achieve a com-
plete elimination of the tumour. In order 
to enhance the efficacy of suicide gene 
therapy one tries to combine it with immu-
notherapy. We have demonstrated that 
IL-6 and GM-CSF enhances the suicide 
effect of TK in a murine model of mali-
gnant melanoma [28] 
   Other genes used in suicide gene the-
rapy trials are: Cytosine deaminase, which 
converts a prodrug – 5-Fluorocytosine into 
5-Fluorouracil; cytochrome P-450 (con-
verts Cyclophosphamide into Phosphora-
mide mustard) and nitroreductase. 
 
ADMINISTRATION OF TUMOUR 
SUPPRESSOR GENES 
 
   The essence of a neoplastic transfor-
mation of healthy cells is a mutation within 
two classes of genes: protooncogenes and 
suppressor genes. Proteins encoded by 
mutated protooncogenes deliver a signal 
to the nucleus and subsequently induce 
cellular divisions. On the other hand, pro-
teins encoded by mutated suppressor 
genes are unable to inhibit protoonco-
gene-induced proliferation. Such a trans-
formed cell dynamically proliferates and 
forms a tumour. Several researchers had 
demonstrated that administration of intact 
suppressor genes into cancer cells reverts 
their neoplastic properties and induces 
tumour regression. However, clinical out-
come of such therapies is not satisfactory, 
mostly because of low transduction effi-
ciency achieved with currently available 
gene delivery systems. In order to elimi-
nate all cancer cells, each of them must be 
modified with an intact suppressor gene. 
In case there is one unmodified cell left, 
it may further proliferate and form new 
tumours. However, Xu et al. demonstrated 
that liposome-mediated transfer of the p53 
gene to mammary tumours in mice led 
to less than 5% tumour cell transfection, 
but was associated with a strong regre-
ssion of tumours. It was shown that rela-
tively low expression of p53 gene within 
the tumour mass induced a strong 
reduction in the number of blood vessels 
in the treated tumours [29]. Other supper-
ssor genes used in cancer gene therapy 
are: BRCA1 in ovarian cancer, prostate 
cancer and breast cancer carried out by 
Holt JT et al. [30,31], and p16 in pancre-
atic and prostate cancer Vieweg J. et al 
[32,33]. 
   Another approach to suppressor gene 
therapy of cancer is the application of mu-
tated adenovirus. The early adenoviral 
E1b sequence is responsible for turning 
off a p53-mediated apoptosis upon entry 
of an adenovirus into a cell. Apoptotic 
death of infected cells, prevents from viral 
replication. ∆E1b adenovirus administered 
to cancer patients may replicate only 
in cancer cells. which lack the functional 
p53 gene. Viruses may replicate in them, 
elucidate a cytopathic effect, and subse-
quently infect and destroy the rest of can-
cer cells [34,35].  
 
ANTIANGIOGENIC GENE THERAPY 
 
   Tumours require efficient blood supply 
in order to grow. Inhibition of angiogenesis 
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is a promising strategy for treating cancer 
patients. Although numerous endogenous 
angiogenesis inhibitors have been disco-
vered, the clinical evaluation of these 
agents has been hindered by high dose 
requirements, manufacturing constraints, 
and relative instability of the corresponding 
recombinant proteins. Antiangiogenic the-
rapy is directed specifically against micro-
vascular endothelial cells that have been 
recruited into the tumour bed. Specific 
antiangiogenic therapy has little or no toxi-
city, does not require that the therapeutic 
agent enters any tumour cells nor cross 
the blood-brain barrier. It controls tumour 
growth independently of tumour cell type, 
and does not induce acquired drug resi-
stance [36]. The delivery of genes enco-
ding antiangiogenic proteins seems to be 
a promising approach, avoiding obstacles 
associated with systemic administration 
of such drugs. Therapeutic genes enoding 
antiangiogenic agents can be delivered 
into patients by different systems e.g. re-
combinant adenoviruses [37] or liposomes 
[38]. Antiangiogenic gene therapy may be 
performed as a systemic or local treat-
ment. Scientists still argue over the best 
way of administration. Local (intratumou-
ral) administration is associated with 
a strong “bystander effect which augments 
the angiostatic activity of introduced ge-
nes” [29] and should not be associated 
with potential side effects of systemic the-
rapy. On the other hand, systemic admini-
stration of genes encoding antiangiogenic 
factors, makes possible a long-lasting 
elevation of, e.g. endostatin levels in blood 
[40]. Thus could it be a proper treatment (i) 
after surgery or radiotherapy to prevent re-
currence of distant metastases, (ii) in com-
bination with chemotherapy (iii) in combi-
nation with vaccine therapy or immuno-
therapy, or (iv) in combination with other 
types of gene therapy, for example, deli-
very of tumour suppressor genes.  
   Antiangiogenic therapy may be divided 
into two strategies. Direct antiangiogenic 
therapy targets endothelial cells (applica-
tion of angiostatin or endostatin), whereas 
indirect therapy interferes with a tumour-
derived angiogenic factor or the receptor 
for it (administration of gene encoding 
a truncated form of native soluble FLT-1 
(endothelium-specific receptor tyrosine ki-
nase), which is a receptor for VEGF) [41]. 
THE FUTURE PROSPECTS 
 
   Although a dramatic progress in cancer 
treatment took place in the last century, 
the effects of therapies are still not satis-
factory. However, a dynamic development 
of several approaches to cancer gene 
therapy over the last two decades seems 
to signal a future breakthrough in onco-
logy. Novel, much more effective gene 
delivery systems will soon be used in cli-
nical trials. Lentiviral vectors, which are 
derived from a deadly virus, despite some 
temporary safety concerns will surely enter 
oncological clinics. Studies carried out 
in animal models will further modify current 
clinical protocols. Probably, several cancer 
gene therapy strategies will have to be 
combined in order to make the ‘escape’ 
of cancer cells from one particular treat-
ment impossible. New tumour-associated 
antigens, construction of ‘designer’ cyto-
kines and a better understanding of immu-
nological processes will undoubtedly con-
tribute to greater advancement in immuno-
gene therapy. New discoveries in mole-
cular biology will also provide new con-
cepts for novel approaches in gene the-
rapy of malignancies. 
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